Literature DB >> 17210187

An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.

Sonja R Surman1, Peter L Collins, Brian R Murphy, Mario H Skiadopoulos.   

Abstract

We describe a method for the generation of clinical grade, live-attenuated vaccines in Vero cells entirely from cDNA plasmids. The entire electroporation procedure can be completed in less than 15 minutes and this is a significant improvement over previous lipid or electroporation based transfection techniques that also involve a heat-shock step. Importantly, the virus preparations can be generated with a minimal use of animal product derived materials, an important consideration for a vaccine candidate that is to be tested in humans. Since it is likely that all live-attenuated parainfluenza virus and pneumovirus vaccines in the future will be generated using reverse genetics, this simplified method provides guidance on how this can be achieved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210187     DOI: 10.1016/j.jviromet.2006.11.024

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

Review 1.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

2.  Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.

Authors:  Susan E Witko; J Erik Johnson; Narender K Kalyan; Barbara K Felber; George N Pavlakis; Maninder K Sidhu; R Michael Hendry; Stephen A Udem; Christopher L Parks
Journal:  J Virol Methods       Date:  2009-11-24       Impact factor: 2.014

3.  Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease.

Authors:  Peter L Collins; Rachel Fearns; Barney S Graham
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

4.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

5.  Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine.

Authors:  Irina Tretyakova; Igor S Lukashevich; Pamela Glass; Eryu Wang; Scott Weaver; Peter Pushko
Journal:  Vaccine       Date:  2012-12-31       Impact factor: 3.641

6.  Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children.

Authors:  Ruth A Karron; Jocelyn San Mateo; Bhagvanji Thumar; Anne Schaap-Nutt; Ursula J Buchholz; Alexander C Schmidt; Emmalene J Bartlett; Brian R Murphy; Peter L Collins
Journal:  J Pediatric Infect Dis Soc       Date:  2014-11-12       Impact factor: 3.164

7.  Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Authors:  Ruth A Karron; Bhagvanji Thumar; Elizabeth Schappell; Sonja Surman; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  Vaccine       Date:  2011-12-14       Impact factor: 3.641

8.  Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.

Authors:  Emmalene J Bartlett; Adam Castaño; Sonja R Surman; Peter L Collins; Mario H Skiadopoulos; Brian R Murphy
Journal:  Virol J       Date:  2007-07-02       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.